JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 255.83 Billion KRW | 1.14% |
| 2022 | 252.94 Billion KRW | 15.25% |
| 2021 | 219.46 Billion KRW | 2.36% |
| 2020 | 214.4 Billion KRW | 6.45% |
| 2019 | 201.4 Billion KRW | 0.27% |
| 2018 | 200.85 Billion KRW | 1.17% |
| 2017 | 198.53 Billion KRW | 3.27% |
| 2016 | 192.24 Billion KRW | 6.87% |
| 2015 | 179.88 Billion KRW | 9.79% |
| 2014 | 163.84 Billion KRW | 6.23% |
| 2013 | 154.23 Billion KRW | -1.17% |
| 2012 | 156.05 Billion KRW | -6.87% |
| 2011 | 167.57 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 260.39 Billion KRW | -1.34% |
| 2024 Q1 | 263.92 Billion KRW | 3.16% |
| 2023 Q4 | 255.83 Billion KRW | 2.34% |
| 2023 Q3 | 249.98 Billion KRW | 2.68% |
| 2023 Q1 | 261.38 Billion KRW | 3.34% |
| 2023 FY | 255.83 Billion KRW | 1.14% |
| 2023 Q2 | 243.45 Billion KRW | -6.86% |
| 2022 Q1 | 229.93 Billion KRW | 4.77% |
| 2022 FY | 252.94 Billion KRW | 15.25% |
| 2022 Q2 | 245.56 Billion KRW | 6.8% |
| 2022 Q3 | 247.58 Billion KRW | 0.82% |
| 2022 Q4 | 252.94 Billion KRW | 2.17% |
| 2021 FY | 219.46 Billion KRW | 2.36% |
| 2021 Q1 | 214.65 Billion KRW | 0.12% |
| 2021 Q2 | 215.35 Billion KRW | 0.33% |
| 2021 Q3 | 216.18 Billion KRW | 0.38% |
| 2021 Q4 | 219.46 Billion KRW | 1.52% |
| 2020 FY | 214.4 Billion KRW | 6.45% |
| 2020 Q1 | 202.85 Billion KRW | 0.72% |
| 2020 Q2 | 242.17 Billion KRW | 19.38% |
| 2020 Q3 | 220.54 Billion KRW | -8.93% |
| 2020 Q4 | 214.4 Billion KRW | -2.79% |
| 2019 Q3 | 198.51 Billion KRW | -3.73% |
| 2019 Q1 | 210.06 Billion KRW | 4.58% |
| 2019 FY | 201.4 Billion KRW | 0.27% |
| 2019 Q4 | 201.4 Billion KRW | 1.46% |
| 2019 Q2 | 206.19 Billion KRW | -1.84% |
| 2018 Q3 | 199.08 Billion KRW | 6.36% |
| 2018 FY | 200.85 Billion KRW | 1.17% |
| 2018 Q4 | 200.85 Billion KRW | 0.89% |
| 2018 Q2 | 187.17 Billion KRW | -4.51% |
| 2018 Q1 | 196.01 Billion KRW | -1.27% |
| 2017 Q1 | 184.38 Billion KRW | -4.09% |
| 2017 Q2 | 183.87 Billion KRW | -0.28% |
| 2017 Q3 | 197.44 Billion KRW | 7.38% |
| 2017 Q4 | 198.53 Billion KRW | 0.55% |
| 2017 FY | 198.53 Billion KRW | 3.27% |
| 2016 FY | 192.24 Billion KRW | 6.87% |
| 2016 Q4 | 192.24 Billion KRW | 7.33% |
| 2016 Q3 | 179.11 Billion KRW | -1.33% |
| 2016 Q2 | 181.53 Billion KRW | 0.0% |
| 2015 Q4 | 179.88 Billion KRW | 0.0% |
| 2015 FY | 179.88 Billion KRW | 9.79% |
| 2014 FY | 163.84 Billion KRW | 6.23% |
| 2013 FY | 154.23 Billion KRW | -1.17% |
| 2012 FY | 156.05 Billion KRW | -6.87% |
| 2011 FY | 167.57 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -29.071% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 86.928% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 70.828% |
| HANDOK Inc. | 790.33 Billion KRW | 67.63% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -49.945% |
| Yuhan Corporation | 2814.07 Billion KRW | 90.909% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 80.548% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -173.683% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 86.894% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -6.711% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 45.439% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -122.518% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -8.154% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 26.565% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -29.071% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 38.969% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 48.81% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 56.594% |
| JW Holdings Corporation | 1176.26 Billion KRW | 78.25% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 58.146% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 81.758% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 60.338% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 26.921% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -66.083% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 30.982% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 47.502% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -29.071% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 76.269% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 85.549% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 60.338% |
| Yuhan Corporation | 2814.07 Billion KRW | 90.909% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 70.928% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -12.902% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 74.255% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 60.338% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 39.072% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 45.434% |
| CKD Bio Corp. | 293.78 Billion KRW | 12.917% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 49.638% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 54.717% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 36.236% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 26.921% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 82.429% |
| Boryung Corporation | 922.36 Billion KRW | 72.263% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 42.179% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 45.439% |